BioMarin Pharmaceutical Inc (BMRN) company profile
Close on Nov 17, 2026Market cap $11.33BP/E 154.0Yield –
About BioMarin Pharmaceutical
Pharmaceutical Preparations, SIC 2834
BioMarin Pharmaceutical Inc. develops and commercializes therapies targeting serious genetic conditions and rare diseases. The biotechnology company organizes its commercial operations into two core business units: Skeletal Conditions and Enzyme Therapies. Key commercial products include VOXZOGO for achondroplasia, alongside enzyme replacement treatments such as VIMIZIM, NAGLAZYME, PALYNZIQ, ALDURAZYME, BRINEURA, and KUVAN. Its customer base consists of specialty pharmacies, hospitals, non-U.S. government entities, pharmaceutical wholesalers, and authorized international distributors, with Sanofi acting as the exclusive distributor and customer for ALDURAZYME.
The company operates globally, conducting direct sales in the United States, Europe, and South America, while serving additional international territories through third-party distribution partners. Its manufacturing infrastructure includes specialized production facilities located in Novato, California, and Shanbally, Cork, Ireland, supplemented by external contract manufacturing organizations. BioMarin Pharmaceutical Inc. maintains its corporate headquarters in San Rafael, California.
Summary of the business section of BioMarin Pharmaceutical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BioMarin Pharmaceutical Inc
- Founded
- 1997
- Headquarters
- Novato, CA
- Address
- 105 Digital Drive 94949
- Phone
- (415) 506-6700
- Website
- www.biomarin.com
- Employees
- 3,221, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Francisco, California
Stock & identifiers
- Ticker
- BMRN
- Exchange
- Nasdaq
- IPO date
- Jul 26, 1999
- Shares outstanding
- 194M, Jul 28, 2026
- Public float
- $6.70B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1048477
- CUSIP
- 09061G101
- ISIN
- US09061G1013
- FIGI
- BBG000CZWZ05
- Share class FIGI
- BBG001S76R05
- LEI
- NSLL8ITTRR0J5HEMR848
- EIN
- 68-0397820
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Alexander Hardy | Chief Executive Officer, Director | 214,635 |
| Gregory R. Friberg | EVP, Chief R&D Officer | 47,732 |
| George Eric Davis | EVP, Chief Legal Officer | 61,003 |
| Cristin Hubbard | EVP, Chief Commercial Officer | 42,472 |
| Charles Greg Guyer | EVP, Chief Technical Officer | 84,140 |
| Brian Mueller | EVP, Chief Financial Officer | 123,314 |
| Rashmi Virendra Ramchandani | VP, Chief Accounting Officer | 25,610 |
| Erin Burkhart | GVP, Chief Accounting Officer | 14,173 |
| Robert M. Plenge | Director | 6,140 |
| Mark J. Enyedy | Director | 21,040 |
| Athena Countouriotis | Director | 21,040 |
| Maykin Ho | Director | 35,500 |
| Willard H. Dere | Director | 46,440 |
| Barbara W. Bodem | Director | 21,045 |
| Robert J. Hombach | Director | 49,360 |
| Elizabeth M. Anderson | Director | 41,940 |
| Timothy P. Walbert | Director | 17,686 |
| Ian T. Clark | Director | 14,490 |
| Richard A. Meier | Director | 126,926 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $21.93M | $12.21M | $6.35M | $68 | $125 |
| FY2024 | $14.85M | $2.42M | $6.57M | $75 | $93 |
| FY2023 Alexander Hardy | $17.88M | $18.52M | $6.32M | $110 | $94 |
| FY2023 Jean Jacques Bienaime | $21.98M | $15.76M | $6.32M | $110 | $94 |
| FY2022 | $18.35M | $34.38M | $6.11M | $118 | $90 |
| FY2021 | $18.26M | $18.39M | $5.51M | $101 | $100 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Alexander Hardy President and CEO | $1.13M | $16.83M | $1.91M | $1.64M | $409.36K | $21.93M | +48% |
| Brian R. Mueller Executive Vice President, CFO | $721.15K | $4.33M | $1.19M | $565.50K | $22.89K | $6.83M | +24% |
| Gregory R. Friberg, M.D. Executive Vice President, Chief Research & Development Officer | $705.65K | $4.62M | $1.27M | $424.20K | $153.20K | $7.17M | -1% |
| C. Greg Guyer, Ph.D. Executive Vice President, Chief Technical Officer | $697.12K | $3.46M | $954.81K | $546.00K | $29.59K | $5.69M | +13% |
| Cristin Hubbard Executive Vice President, Chief Commercial Officer | $662.31K | $3.46M | $954.81K | $562.80K | $69.62K | $5.71M | -18% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 3,221 employees worldwide, of whom 1,518 were in operations, 692 were in research and development, 495 were in sales and marketing and 516 were in administration.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?